Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Equity Average (2017 - 2025)

Historic Equity Average for Spero Therapeutics (SPRO) over the last 9 years, with Q3 2025 value amounting to $29.7 million.

  • Spero Therapeutics' Equity Average fell 5937.04% to $29.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.7 million, marking a year-over-year decrease of 5937.04%. This contributed to the annual value of $76.5 million for FY2024, which is 1630.55% down from last year.
  • Latest data reveals that Spero Therapeutics reported Equity Average of $29.7 million as of Q3 2025, which was down 5937.04% from $33.3 million recorded in Q2 2025.
  • In the past 5 years, Spero Therapeutics' Equity Average registered a high of $125.4 million during Q1 2021, and its lowest value of $29.7 million during Q3 2025.
  • In the last 5 years, Spero Therapeutics' Equity Average had a median value of $70.4 million in 2023 and averaged $70.0 million.
  • Per our database at Business Quant, Spero Therapeutics' Equity Average soared by 5979.9% in 2021 and then crashed by 6615.98% in 2022.
  • Spero Therapeutics' Equity Average (Quarter) stood at $100.1 million in 2021, then plummeted by 45.84% to $54.2 million in 2022, then skyrocketed by 48.13% to $80.3 million in 2023, then tumbled by 30.49% to $55.8 million in 2024, then tumbled by 46.86% to $29.7 million in 2025.
  • Its Equity Average stands at $29.7 million for Q3 2025, versus $33.3 million for Q2 2025 and $40.0 million for Q1 2025.